Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (brevity).

Gibb, AdamPirrie, SLinton, Kim MPaterson, KDavies, ACollins, GMenne,TMcKay, PFields, PMiall, FNagy, EWheatly, KWarbey, VBarrington, SRadford, John A2017-04-022017-04-022016Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin Lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (brevity). 2016, 101:20 Haematologicahttp://hdl.handle.net/10541/620225enPreliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (brevity).Meetings and ProceedingsHaematologica